Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYunfei LvKCKuang ChenGWGongqiang Wu

Discussion

Loading...

Member takes

Overview

Multicenter study shows high response rates for glofitamab in relapsed aggressive B-cell lymphoma, indicating manageable adverse events.

Key Points

  • To evaluate the efficacy and safety of glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma and identify predictive factors for response.
  • Retrospective, multicenter study with 65 patients
  • Evaluated patients treated with glofitamab-based regimens
  • Analyzed overall response rate, complete response rate, and survival outcomes using Kaplan-Meier method
  • Performed univariate logistic regression analysis for predictors of complete response
  • Overall response rate (ORR) was 67.4% with a complete response (CR) rate of 46.5%
  • Median progression-free survival (PFS) was 6.0 months
  • Median overall survival (OS) was 13.9 months
  • Most frequent grade ≥3 adverse events included anemia (18.2%) and neutropenia (15.9%)
  • Cytokine release syndrome occurred in 18.2% of patients, primarily low-grade

Cite This Study

Lv et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbe3https://doi.org/10.1182/blood-2025-7253
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study2025
  2. 2Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  3. 3Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  4. 4Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma2025
  5. 5TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma2026